President Trump's executive order is giving psychedelic stocks a boost. These companies are leaders in the industry.

The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly’s expansion into cancer treatments.

Donald Trump's order on psychedelic drugs sent shares of companies in the space surging. RFK Jr and Joe Rogan were present at ...

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

Why Wall Street loves Lilly. So what does this Wall Street analyst like about Lilly? Yesterday, Eli Lilly announced it will ...

Let's look at a smaller and a larger company today, highlighting the benefits and risks of each. The small-cap stock is ...

Nonetheless, there may still be room for the stock to get back to $1 trillion if its financial results get a boost from ...

The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.8% annually through 2033, ...

Drug companies must continue to fill their pipelines. Lilly recently made three key deals. Will AI create the world's first trillionaire? Our team just released a report on the one little-known ...

The diabetes and weight?loss drug market has entered 2026 with extraordinary momentum, building on the explosive growth seen throughout 2025. According to global health information technology and ...

Generate:Biomedicines (NASDAQ: GENB), the drug developer focused on creating immunology and inflammation (I&I) and oncology treatments through its own artificial intelligence (AI)-based platform, has ...

Replimune Group shares collapsed nearly 60% in premarket trading on Monday after the U.S. Food and Drug Administration (FDA) issued a second complete response letter (RPL) for RP1, the company’s ...